Combinations of AKT inhibitor compounds and chemotherapeutic agents, and methods of use
US10092567B2 · kind B2 · utility
2Cited by
48References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 21, 2017 |
| Grant date | Oct 9, 2018 |
| Priority date | — |
| Expiry date | Feb 21, 2037 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61K2039/505
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.